信必可都保治疗支气管哮喘53例临床观察

Clinical Observation on the Effect of Symbicort Turbuhaler for Bronchial Asthma

目的:观察吸入信必可都保(布地奈德+福莫特罗)治疗支气管哮喘的临床疗效和安全性。方法:53例未达到控制的支气管哮喘患者接受信必可都保吸入治疗,于治药前、治疗后4、8、12周监测第1秒用力呼气容积(FEV1)和最大呼气流速(PEF)值动态变化。结果:98.1%的患者病情得到控制;治疗后4、8、12周FEV1和PEF均有显著改善(P均<0.001);未见明显不良反应。结论:信必可都保治疗哮喘疗效显著、安全性好。

Objective:To investigate the clinical effect of symbicort turbuhaler on bronchial asthma and its safety. Methods: Fifty-three patients with bronchial asthma received symbicort turbuhaler treatment.The forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF) were monitored before treatment, 4th week, 8th week and 12th week after treatment.Results:The total effectiveness rate was 98.1%,FEV1 and PEF were obviously improved in 4th week,8th week and 12th week after treatment(all P<0.001),and had few side effects occurred. Conclusion: Symbicort turbuhaler is safe and effective for bronchial asthma.